Markets applaud strong finish to 2025 and better-than-expected 2026 outlook
12/02/26 -"Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed consensus expectations, boosting investor ..."
Pages
50
Language
English
Published on
12/02/26
You may also be interested by these reports :
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...
05/03/26
Who would have believed that amongst the star-studded European pharma names, the tiny (in market cap terms, relative to Big Pharmas) Faes Farma (ADD; ...
04/03/26
The Q4 results exceeded expectations, with Crop Science being a key top-line driver. Adjusted EBITDA declined for all three divisions. While the 2026 ...